Daiwa Securities Group
ABCL icon

Daiwa Securities Group’s AbCellera Biologics ABCL Stock Holding History

Daiwa Securities Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,151
Closed -$4K – 1177
2025
Q4 		$4K Hold
1,151
– – ﹤0.01% 1248
2025
Q3 		$6K Hold
1,151
– – ﹤0.01% 1185
2025
Q2 		$4K Hold
1,151
– – ﹤0.01% 1161
2025
Q1 		$3K Hold
1,151
– – ﹤0.01% 1158
2024
Q4 		$3K Hold
1,151
– – ﹤0.01% 1184
2024
Q3 		$3K Hold
1,151
– – ﹤0.01% 1193
2024
Q2 		$3K Hold
1,151
– – ﹤0.01% 1221
2024
Q1 		$5K Hold
1,151
– – ﹤0.01% 1200
2023
Q4 		$7K Hold
1,151
– – ﹤0.01% 1184
2023
Q3 		$5K Hold
1,151
– – ﹤0.01% 1150
2023
Q2 		$7K Hold
1,151
– – ﹤0.01% 1153
2023
Q1 		$9K Hold
1,151
– – ﹤0.01% 1113
2022
Q4 		$12K Buy
1,151
+91
+9% +$1.05K ﹤0.01% 1103
2022
Q3 		$10K Hold
1,060
– – ﹤0.01% 1124
2022
Q2 		$11K Buy
1,060
+238
+29% +$2.02K ﹤0.01% 1135
2022
Q1 		$8K Hold
822
– – ﹤0.01% 1146
2021
Q4 		$12K Buy
+822
New +$12.5K ﹤0.01% 1139

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Daiwa Securities Group's ABCL Position: Q1 2026 in Review

Daiwa Securities Group sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 1,151 shares — an estimated $4K sold.

Daiwa Securities Group first reported a position in ABCL in Q4 2021 and held it in 17 quarters. The position peaked at $12K in Q4 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Daiwa Securities Group reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 1,151 AbCellera Biologics shares in Q1 2026, an estimated $4K.
  • Daiwa Securities Group first reported a position in AbCellera Biologics in Q4 2021 and held it in 17 quarters.
  • Daiwa Securities Group's AbCellera Biologics position peaked at $12K in Q4 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.